Accendra Health, Inc.
NYSE:ACHMedical - Distribution
+$0.12 today
- Market cap
- $54.22M
- Beta
- 1.63
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$14.11
Volume 1.41M
Average 0.83M
ACH Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
Accendra Health, Inc.NYSE: ACH
Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026
Change in working capital dips below year-ago levels
Q1 FY2026 change in working capital of $55.63M (cash outflow) fell 32.0% year over year, behind the +902.4% change in trailing-twelve-month change in working capital. Over 3 fiscal years it compounded at -10.1% a year.
Context
- Change in working capital amounted to 2.4% of revenue in FY2025, up 2.1 pp from a year earlier.
- Change in working capital increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -32.0% toward the trailing-twelve-month pace of +902.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2025
- 65.21M USD
- Year-over-year change
- +356.3%
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 65.21M | +356.3% |
| FY2024 | 2024-12-31 | (25.44M) | -104.9% |
| FY2023 | 2023-12-31 | 522.29M | +481.8% |
| FY2022 | 2022-12-31 | 89.77M | +134.3% |
| FY2021 | 2021-12-31 | (261.4M) | — |
Change in Working Capital vs competitors
How ACH compares with its peers on the latest reported figures
- Peers report in different currencies, so change in working capital is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +902.4% is the 2nd highest of 11, against a peer median of -138.8%.
- Change in working capital amounts to 3.6% of revenue for ACH, versus a peer median of 10.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $96.43M USD | +902.4% | -10.1% | 3.6% | |
| LTM Mar 2026 | $50.69M USD | -411.7% | — | 131.0% | |
| LTM Mar 2026 | CA$20.24M CAD | +163.3% | -29.5% | 6.5% | |
| LTM Mar 2026 | $16.29M USD | +228.1% | — | 13.9% | |
| LTM Mar 2026 | $15.79M USD | +1014.2% | — | — | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $10.29M USD | -223.3% | — | 99.7% |
| LTM Mar 2026 | $6.7M USD | -348.8% | -55.5% | — | |
| LTM Apr 2026 | CA$3.85M CAD | -1150.7% | -60.1% | 0.6% | |
| LTM Mar 2026 | $2.98M USD | -83.4% | — | 35.6% | |
| LTM Mar 2026 | $1.06M USD | -194.1% | +3.9% | 1.3% | |
| LTM Mar 2026 | $451K USD | +162.6% | — | 0.8% | |
| Peer median (excluding ACH) | — | -138.8% | -42.5% | 10.2% | |
Competitors are the stored peer set for ACH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 221.59M | 22.39M | (41.3M) | (362.69M) | (102.68M) |
| Depreciation & Amortization | 90.62M | 228.67M | 287.38M | 264.78M | 214.52M |
| Deferred Income Tax | (29.74M) | (26.36M) | (23.65M) | (26.12M) | (17.89M) |
| Stock-Based Compensation | 25.02M | 20.99M | 23.22M | 26.84M | 12.87M |
| Change in Working Capital | (261.4M) | 89.77M | 522.29M | (25.44M) | 65.21M |
| Accounts Receivables | (2.2M) | 1.1M | 166.58M | (94.55M) | 122.36M |
| Inventory | (263.44M) | 166.56M | 224.34M | (26.23M) | (6.85M) |
| Accounts Payables | 3.55M | 13.65M | 31M | 65.19M | 6.48M |
| Other Working Capital | 692K | (91.54M) | 100.37M | 30.15M | (56.78M) |
| Other Non-Cash Items | 78.09M | (10.45M) | (27.22M) | 284.12M | (273.83M) |
| Operating Cash Flow | 124.18M | 325.01M | 740.71M | 161.5M | (101.79M) |
| Capital Expenditures | (49.69M) | (166.58M) | (207.89M) | (228.16M) | (201.33M) |
| Acquisitions (Net) | (43.37M) | (1.68B) | 0 | 0 | 324.26M |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 39.43M | 46.71M | 53.62M | 94.33M | 11.12M |
| Investing Cash Flow | (53.63M) | (1.8B) | (137.25M) | (116.53M) | 144.42M |
| Debt Repayment | (95.35M) | 1.58B | (416.69M) | (244.2M) | 203.5M |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (10.18M) |
| Dividends Paid | (731K) | 0 | 0 | 0 | 0 |
| Other Financing Activities | (33.4M) | (85.4M) | (637K) | (23.41M) | (5.24M) |
| Financing Cash Flow | (129.48M) | 1.5B | (417.33M) | (267.6M) | 188.08M |
| Effect of Forex Changes | (3.54M) | (3.49M) | 613K | (901K) | 1.9M |
| Net Change in Cash | (62.47M) | 14.15M | 186.74M | (223.54M) | 232.61M |
| Free Cash Flow | 74.49M | 158.42M | 532.82M | (66.67M) | (303.12M) |
Accendra Health, Inc.
NYSE:ACH
Intrinsic Alpha fair value
Locked
Current Price
$0.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.